File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of palmitoyl carnitine and structural analogs on arterial blood pressure in the rat. A comparison with platelet-activating factor

TitleEffects of palmitoyl carnitine and structural analogs on arterial blood pressure in the rat. A comparison with platelet-activating factor
Authors
Issue Date1991
Citation
Journal Of Lipid Mediators, 1991, v. 3 n. 2, p. 205-214 How to Cite?
AbstractPalmitoyl carnitine and lysophosphatidylcholine have been implicated in the generation of cardiac arrhythmias in the ischemic myocardium. These amphiphilic compounds are structurally similar to platelet-activating factor (PAF). The present study compared the hypotensive effect of these compounds to PAF in the anesthetized rat. Palmitoyl carnitine was about 1000 times less potent than PAF in lowering the blood pressure. Lysophosphatidylcholine and other structurally related compounds, in dosages similar to that of palmitoyl carnitine, had no significant hypotensive action. CV 3988, a PAF antagonist, blocked the hypotensive action of PAF but had no effect on the hypotensive action of palmitoyl carnitine. This suggested the effect of palmitoyl carnitine was not associated with the same site or mechanism as PAF. The results also ruled out the involvement of prostaglandin formation and of the sympathetic nervous system since indomethacin, phenoxy-benzamine and propranolol did not affect the hypotensive action of palmitoyl carnitine. In addition, it is unlikely that palmitoyl carnitine exerted its effect by a direct membrane-perturbing action because lysophosphatidylcholine, which possesses similar amphiphilic properties, does not share the same hypotensive effect.
Persistent Identifierhttp://hdl.handle.net/10722/171025
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMan, RYKen_US
dc.contributor.authorHu, Wen_US
dc.contributor.authorMock, Ten_US
dc.contributor.authorKinnaird, AAAen_US
dc.date.accessioned2012-10-30T06:11:52Z-
dc.date.available2012-10-30T06:11:52Z-
dc.date.issued1991en_US
dc.identifier.citationJournal Of Lipid Mediators, 1991, v. 3 n. 2, p. 205-214en_US
dc.identifier.issn0921-8319en_US
dc.identifier.urihttp://hdl.handle.net/10722/171025-
dc.description.abstractPalmitoyl carnitine and lysophosphatidylcholine have been implicated in the generation of cardiac arrhythmias in the ischemic myocardium. These amphiphilic compounds are structurally similar to platelet-activating factor (PAF). The present study compared the hypotensive effect of these compounds to PAF in the anesthetized rat. Palmitoyl carnitine was about 1000 times less potent than PAF in lowering the blood pressure. Lysophosphatidylcholine and other structurally related compounds, in dosages similar to that of palmitoyl carnitine, had no significant hypotensive action. CV 3988, a PAF antagonist, blocked the hypotensive action of PAF but had no effect on the hypotensive action of palmitoyl carnitine. This suggested the effect of palmitoyl carnitine was not associated with the same site or mechanism as PAF. The results also ruled out the involvement of prostaglandin formation and of the sympathetic nervous system since indomethacin, phenoxy-benzamine and propranolol did not affect the hypotensive action of palmitoyl carnitine. In addition, it is unlikely that palmitoyl carnitine exerted its effect by a direct membrane-perturbing action because lysophosphatidylcholine, which possesses similar amphiphilic properties, does not share the same hypotensive effect.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Lipid Mediatorsen_US
dc.subject.meshAdrenergic Alpha-Antagonists - Pharmacologyen_US
dc.subject.meshAdrenergic Beta-Antagonists - Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshHypotension - Physiopathologyen_US
dc.subject.meshIndomethacin - Pharmacologyen_US
dc.subject.meshLysophosphatidylcholines - Pharmacologyen_US
dc.subject.meshPalmitoylcarnitine - Pharmacologyen_US
dc.subject.meshPhenoxybenzamine - Pharmacologyen_US
dc.subject.meshPhospholipid Ethers - Pharmacologyen_US
dc.subject.meshPlatelet Activating Factor - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshPropranolol - Pharmacologyen_US
dc.subject.meshRatsen_US
dc.subject.meshSerum Albumin, Bovine - Pharmacologyen_US
dc.titleEffects of palmitoyl carnitine and structural analogs on arterial blood pressure in the rat. A comparison with platelet-activating factoren_US
dc.typeArticleen_US
dc.identifier.emailMan, RYK:rykman@hkucc.hku.hken_US
dc.identifier.authorityMan, RYK=rp00236en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1686730-
dc.identifier.scopuseid_2-s2.0-0026035151en_US
dc.identifier.volume3en_US
dc.identifier.issue2en_US
dc.identifier.spage205en_US
dc.identifier.epage214en_US
dc.identifier.isiWOS:A1991FC46100008-
dc.identifier.scopusauthoridMan, RYK=7004986435en_US
dc.identifier.scopusauthoridHu, W=7404360099en_US
dc.identifier.scopusauthoridMock, T=35954418100en_US
dc.identifier.scopusauthoridKinnaird, AAA=6603472891en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats